Evidence desk
The evidence behind the decisions
Guidelines, primary studies and drug labels, with their different roles kept visible.
01 · ACR guideline for management of gout
ULT indications, initial therapy, targets and prophylaxis.
Open original source ↗02 · NICE NG219: Gout—recommendations
Diagnosis, repeat urate after a flare, titration and severe-disease targets.
Open original source ↗03 · EULAR recommendations on imaging in crystal-induced arthropathies
Modality selection and distinction between deposition and symptoms.
Open original source ↗04 · ACR/EULAR CPPD classification criteria
Research classification; not a standalone diagnostic test.
Open original source ↗05 · EULAR CPPD recommendations: terminology and diagnosis
Phenotypes and associated metabolic conditions.
Open original source ↗06 · SANJO: septic arthritis in native joints
Crystals do not exclude infection; aspiration and microbiology priorities.
Open original source ↗07 · ACR patient resource: CPPD
Patient explanation, associations and limits of current therapy.
Open original source ↗08 · Imaging features of CPPD: multidisciplinary consensus definitions
Anatomic imaging features and modality limitations.
Open original source ↗10 · COLCRYS prescribing information
Adult flare regimen, organ impairment and drug interactions; verify product-specific current label before prescribing.
Open original source ↗11 · Updated EULAR recommendations for gout management
Severe-gout target and long-term urate-lowering approach.
Open original source ↗12 · Allopurinol dose escalation to target serum urate
Evidence for monitored escalation rather than a fixed maintenance ceiling.
Open original source ↗13 · Allopurinol prescribing information
Hypersensitivity precautions and thiopurine interactions.
Open original source ↗14 · CARES: cardiovascular safety of febuxostat or allopurinol
Mortality signal in patients with established cardiovascular disease.
Open original source ↗15 · FAST: long-term cardiovascular safety of febuxostat
Different population and design from CARES; noninferiority result.
Open original source ↗16 · Febuxostat prescribing information
Boxed warning, indication restrictions and thiopurine contraindication.
Open original source ↗17 · Nurse-led education and treat-to-target gout care
Education, engagement and a structured treatment pathway.
Open original source ↗18 · KRYSTEXXA prescribing information
Methotrexate co-therapy, G6PD, infusion monitoring and urate stopping guidance.
Open original source ↗19 · COLCHICORT
Short-term colchicine versus prednisone in older hospitalized adults.
Open original source ↗20 · Prednisolone 10 versus 30 mg for acute CPP crystal arthritis
Small comparative dose trial; not a universal dosing protocol.
Open original source ↗21 · EULAR CPPD recommendations: management
Symptom control and prevention; limited underlying trial base.
Open original source ↗22 · Methotrexate in chronic-recurrent CPPD
No significant benefit demonstrated; limits claims for MTX.
Open original source ↗23 · Anakinra versus prednisone in acute CPPD
Small pilot evidence; off-label specialist use is distinct from routine care.
Open original source ↗24 · Histopathology and ultrastructure in Milwaukee shoulder
BCP aggregates and limits of conventional microscopy.
Open original source ↗25 · Lavage with steroid versus sham in calcific shoulder tendinopathy
No benefit over sham in the studied population; procedure counseling.
Open original source ↗26 · Milwaukee shoulder: fifteen additional cases
Destructive arthropathy phenotype and fluid findings.
Open original source ↗27 · Calcium oxalate arthropathy in dialysis
Rare-disease illustration; not comparative treatment evidence.
Open original source ↗28 · DASH-patterned groceries in gout
Dietary intervention remains adjunctive; pilot limitations.
Open original source ↗29 · CPIC: HLA-B genotype and allopurinol dosing — 2015 update
Interpreting HLA-B*58:01 results and selecting an alternative for carriers.
Open original source ↗30 · MSU crystals activate the NALP3/NLRP3 inflammasome
Crystal sensing, caspase-1 and IL-1β activation.
Open original source ↗31 · Synovial cytokines across the stages of acute gout
IL-1β, IL-6, IL-8, TNF and the resolution phase.
Open original source ↗32 · ILARIS (canakinumab) prescribing information
Restricted adult gout-flare indication, 150 mg dose, ≥12-week retreatment interval and infection precautions.
Open original source ↗33 · Anakinra for gout flares: randomized phase II trial
Pain improvement with anakinra versus triamcinolone in patients unsuitable for conventional therapy; no superiority on the primary endpoint.
Open original source ↗34 · KINERET (anakinra) prescribing information
IL-1 receptor blockade, renal clearance, neutrophil and infection monitoring; gout is off-label in the U.S.
Open original source ↗35 · KDIGO guideline for evaluation and management of CKD
Section 3.14: treat symptomatic hyperuricemia; do not use urate lowering solely to delay CKD in asymptomatic hyperuricemia.
Open original source ↗36 · CKD-FIX: allopurinol and CKD progression
No slowing of eGFR decline in the studied progressive-CKD population without gout.
Open original source ↗37 · PERL: allopurinol and kidney function in type 1 diabetes
No clinically meaningful kidney benefit from urate lowering in the studied type 1 diabetes population.
Open original source ↗38 · ALL-HEART: allopurinol in ischemic heart disease
No cardiovascular event reduction in patients with ischemic heart disease without gout.
Open original source ↗39 · LoDoCo2: colchicine in chronic coronary disease
Reduced composite cardiovascular events with 0.5 mg daily in selected chronic coronary disease.
Open original source ↗40 · COLCOT: low-dose colchicine after myocardial infarction
Reduced composite cardiovascular events after recent myocardial infarction in the studied population.
Open original source ↗41 · CLEAR SYNERGY: colchicine in acute myocardial infarction
Neutral cardiovascular primary endpoint; benefit cannot be assumed across all post-MI settings.
Open original source ↗42 · LODOCO (colchicine 0.5 mg) prescribing information
Specific cardiovascular indication, contraindications and interacting medicines.
Open original source ↗43 · CANTOS: IL-1β inhibition in atherosclerotic disease
Cardiovascular proof of concept in post-MI patients with residual inflammation; fatal infection signal.
Open original source ↗44 · Treat-to-target ULT and cardiovascular outcomes in gout
109,504 patients; target achievement associated with fewer cardiovascular events; not randomized proof of protection.
Open original source ↗45 · Target serum urate and CKD progression in gout
In gout with stage 3 CKD, target achievement associated with lower severe/end-stage kidney disease risk; residual confounding remains.
Open original source ↗46 · DAPA-CKD: dapagliflozin in chronic kidney disease
Kidney and heart-failure benefits in eligible CKD patients; not a trial of gout treatment.
Open original source ↗47 · SGLT2 inhibitors, recurrent gout flares and mortality
Lower recurrent flare rates in gout with type 2 diabetes; not evidence to replace urate-lowering therapy.
Open original source ↗48 · Purine-rich foods, dairy and incident gout
Different associations for animal purines, purine-rich vegetables and dairy; observational dietary evidence.
Open original source ↗49 · DASH dietary pattern and gout risk
Healthy dietary pattern associated with lower gout risk; prevention cohort is not a gout treatment trial.
Open original source ↗50 · Musculoskeletal Health Australia: gout and CPPD self-care
No evidence that calcium-rich food triggers CPP attacks; maintain appropriate dietary calcium.
Open original source ↗51 · AUA: medical management of kidney stones
Stone-specific treatment: urine alkalinization for uric acid stones and selected allopurinol use.
Open original source ↗52 · Dapansutrile for gout flares
Early proof of concept for direct NLRP3 inhibition; does not establish routine clinical use.
Open original source ↗53 · Probenecid prescribing information
Uricosuric mechanism, renal limitations, stone risk and interactions.
Open original source ↗54 · MIRROR RCT: pegloticase plus methotrexate
Improved sustained urate response with methotrexate co-therapy.
Open original source ↗55 · Gout flares and subsequent cardiovascular events
Transient association after flares; does not by itself establish causation or a preventive drug effect.
Open original source ↗56 · NIAMS: gout diagnosis, treatment and steps to take
Medication roles, dietary changes and management of other health conditions.
Open original source ↗57 · NIAMS: gout symptoms, causes and risk factors
Tophi, tissue damage and associated kidney and cardiovascular disease.
Open original source ↗58 · REDUCE-2: pozdeutinurad (AR882)
Urate response at six months in 811 randomized participants. Conference findings; the urate endpoint does not establish prevention of organ damage.
Open original source ↗59 · Early versus deferred urate-lowering therapy during a flare
Korean trial: 298 randomized, 288 in the modified intention-to-treat analysis. Similar mean pain changes did not meet the prespecified noninferiority criterion.
Open original source ↗60 · SSGJ-613 for acute gout flares
Chinese active-comparator trial of an IL-1β antibody. Conference evidence should not be treated as a U.S. prescribing authorization.
Open original source ↗61 · BAPTIST: interim synovial and clinical findings in CPPD
Early baricitinib study with 11 participants at baseline and nine at week 12; no consistent clinical or patient-reported improvement pattern. Too small and preliminary to establish benefit or safety.
Open original source ↗62 · Smartphone-assisted treat-to-target gout care
Single-center, open-label trial in 280 men: the care package included education, reminders, remote urate monitoring and weekly physician review. Its result cannot be attributed to an app alone.
Open original source ↗63 · ASGARD: anakinra versus methylprednisolone in gout with CKD
Recruitment fell short: 21 randomized and 17 treated. This report informs trial feasibility, not a reliable comparative efficacy conclusion.
Open original source ↗64 · DISSOLVE I and II: nanoencapsulated sirolimus plus pegadricase
Pooled results for 265 treated participants. NASP is a different combination from pegloticase with methotrexate; cross-trial comparisons cannot establish superiority.
Open original source ↗65 · NASP: sponsor report of FDA complete response letter
Sobi reported requests concerning manufacturing controls and facilities. This dated announcement is regulatory context, separate from the efficacy publication.
Open original source ↗66 · NICE: shockwave therapy for calcific shoulder tendinopathy
Efficacy evidence is inadequate; NICE recommends use only in research. Transfer to the HealthTech numbering system did not constitute a new efficacy finding.
Open original source ↗67 · AAOS: calcific tendinitis of the shoulder
Describes nonsurgical care and consideration of surgery for symptoms persisting despite such treatment. It is educational guidance, not a randomized comparison of procedures.
Open original source ↗68 · Hydroxychloroquine for chronic CPPD
A small older study underlies part of the hydroxychloroquine discussion in EULAR 2011. The limited evidence does not establish deposit clearance or a robust long-term disease-modifying effect.
Open original source ↗69 · EULAR management recommendations catalogue
The relevant management frameworks identified in this review remain EULAR gout 2016 and CPPD 2011. Newer classification and imaging recommendations address different questions.
Open original source ↗Educational material, not individual medical advice. This personal publication is not a clinic portal. Urgent problems require direct medical care. Any paid services are private and separate from clinic accounts; they are not billed to insurance.
© Olga Goodman, MD · RheumaView. Copying or redistribution requires author and source credit.